HONOLULU, Dec. 3, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB:
CDXI) and GNC (NYSE: GNC) announced today that they are expanding
the sales and marketing program for ZanthoSyn®, Cardax's premium
astaxanthin dietary supplement for inflammatory health and
longevity. GNC is the exclusive brick-and-mortar retail channel for
ZanthoSyn®.
GNC will augment Cardax's sales and marketing efforts with
additional initiatives to increase ZanthoSyn® product awareness and
education among GNC store associates and valued customers
nationwide.
The program will build on the strong foundation that has already
made ZanthoSyn® a top selling product in Hawaii GNC stores for more
than a year. Strong store sell-through has also been seen in other
major markets where Cardax has implemented its ZanthoSyn® sales and
marketing strategy, including California, Nevada, and New York.
Cardax's two-pronged sales and marketing strategy combines:
- Physician outreach and education, where ZanthoSyn® is
positioned as the first safe, physician friendly, anti-inflammatory
for health and longevity, and GNC serves as a convenient and
credible distribution channel for physicians recommending
ZanthoSyn®.
- GNC store outreach, education, and in-store sales
support, which builds on the ability to utilize ZanthoSyn® as a
foundation of health, wellness, and performance regimens.
"We are very pleased and honored to work with GNC to expand our
national ZanthoSyn® sales and marketing program," said David G. Watumull, Cardax CEO. "GNC has proven
that their knowledgeable sales associates offer a highly effective
channel for rapidly growing awareness and sales of this innovative
product."
About Cardax
Cardax—headquartered in Honolulu,
HI—is focused on developing and commercializing innovative dietary
supplements and pharmaceuticals. The safety and efficacy of
Cardax's products have not been directly evaluated in clinical
trials or confirmed by the FDA.
About ZanthoSyn®
Cardax's first commercial product, ZanthoSyn®, is a physician
recommended anti-inflammatory supplement for health and longevity
that features astaxanthin with enhanced absorption and purity.*
ZanthoSyn® is sold in GNC stores and online. ZanthoSyn® contains
astaxanthin, which is Generally Recognized as Safe (GRAS) according
to FDA regulations.
About Astaxanthin
Astaxanthin is a clinically studied compound with safe
anti-inflammatory activity that supports joint health,
cardiovascular health, metabolic health, liver health, and
longevity.*
About GNC
GNC—headquartered in Pittsburgh,
PA—is a leading global specialty health, wellness, and performance
retailer. GNC connects customers to their best selves by offering a
premium assortment of health, wellness, and performance products,
including protein, performance supplements, weight management
supplements, vitamins, herbs and greens, wellness supplements,
health and beauty, food and drink, and other general merchandise.
This assortment features proprietary GNC and nationally recognized
third-party brands. GNC's diversified, multi-channel business model
generates revenue from product sales through company-owned retail
stores, domestic and international franchise activities,
third-party contract manufacturing, e-commerce, and corporate
partnerships. As of June 30, 2018,
GNC had approximately 8,800 locations, of which approximately 6,600
retail locations are in the United
States (including approximately 2,400 Rite Aid franchise
store-within-a-store locations) and franchise operations in
approximately 50 countries.
Media Contacts
Cardax: Janice Kam,
press@cardaxpharma.com, 1-808-457-1400
GNC: GNC Media, GNCMedia@zenogroup.com, 1-212-284-0455
Safe Harbor
This release may contain certain forward-looking statements
regarding our prospective performance and strategies within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
We intend such forward-looking statements to be covered by the safe
harbor provisions for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995, and are including
this statement for purposes of said safe harbor provisions.
Forward-looking statements, which are based on certain assumptions
and describe future plans, strategies, and expectations of our
company, are generally identified by use of words "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "project,"
"seek," "strive," "try," or future or conditional verbs such as
"could," "may," "should," "will," "would," or similar expressions.
Our ability to predict results or the actual effects of our plans
or strategies is inherently uncertain. Accordingly, actual results
may differ materially from anticipated results. Some of the factors
that could cause our actual results to differ from our expectations
or beliefs include, without limitation, the risks discussed from
time to time in our filings with the Securities and Exchange
Commission. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this release. Except as required by applicable law or
regulation, we undertake no obligation to update these
forward-looking statements to reflect events or circumstances that
occur after the date on which such statements were made.
* These statements have not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat,
cure, or prevent any disease.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cardax-and-gnc-announce-expanded-zanthosyn-sales-and-marketing-program-300758732.html
SOURCE Cardax, Inc.